7,744.25

-39.00

-0.50%

52,876.00

+180.00

+0.34%

29,505.25

-474.25

-1.58%

Russell 2000 Futures

2,849.50

+10.00

+0.35%

5.05

+0.05

+1.04%

16.91

-0.61

-3.48%

4,054.60

+3.00

+0.07%

79,604.05

-1,213.45

-1.50%

Crude Oil Dec 26

101.72

-1.06

-1.03%

US Private Equity

10,940.50

+9.00

+0.08%

Copenhagen - Delayed Quote DKK

Genmab A/S (GMAB.CO)

3,868.00 +871.00 (+29.06%)

At close: October 28 at 4:59:56 PM GMT+1

Loading Chart for GMAB.CO

Chart Range Bar

Interval:

In partnership with ChartIQ

Genmab’s Three Positive Phase III Readouts Set Stage for Potential 2027 Cancer Launches

Genmab’s Three Positive Phase III Readouts Set Stage for Potential 2027 Cancer Launches

Genmab Stock Surges to Record High After Stunning Cancer Drug Results

Genmab Stock Surges to Record High After Stunning Cancer Drug Results

Genmab Stock Hits 52-Week High - Here's Why

Genmab Stock Hits 52-Week High - Here's Why

Top Midday Gainers

Top Midday Gainers

GMAB Stock Hits All-Time High After Genmab’s Cancer Drug Trial Meets Primary Goals — Here’s What Investors Need To Know

GMAB Stock Hits All-Time High After Genmab’s Cancer Drug Trial Meets Primary Goals — Here’s What Investors Need To Know

Genmab stock surges 16% on positive cancer trial results

Genmab stock surges 16% on positive cancer trial results

Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer

Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer

Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer

Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer

J.P. Morgan upgrades Genmab on cancer drug growth potential

J.P. Morgan upgrades Genmab on cancer drug growth potential

Petosemtamab Trial Results May Change The Case For Genmab Stock

Petosemtamab Trial Results May Change The Case For Genmab Stock

Genmab's Encouraging Oncology Data Boosts Investor Optimism

Genmab's Encouraging Oncology Data Boosts Investor Optimism

Mobilize your Website

View Site in Mobile | Classic

Share by: